Ruffer Portfolio holdings
Ruffer is an independent investment manager owned and run by its partners, with a single global strategy aimed at not losing money over any rolling 12-month period. Jonathan Ruffer, who began as a stockbroker and then became a barrister, started it in 1994 with Robert Shirley, 14th Earl Ferrers, and Jane Tufnell, and it became Ruffer LLP in 2004. The firm starts by weighing the risks it sees in markets and picking assets that should protect the portfolio if they come true, then takes on growth mainly through global stocks. It runs a stock-market-listed investment company, and its clients include pension plans, charities and family offices.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$294M |
| 2 |
Freeport-McMoran
FCX
|
+$172M |
| 3 |
eHealth
EHTH
|
+$76.5M |
| 4 |
Dow Inc
DOW
|
+$55.4M |
| 5 |
General Motors
GM
|
+$38.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$318M |
| 2 |
Amgen
AMGN
|
+$218M |
| 3 |
Walt Disney
DIS
|
+$133M |
| 4 |
ATVI
Activision Blizzard
ATVI
|
+$111M |
| 5 |
Cigna
CI
|
+$108M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 32.47% |
| 2 | Healthcare | 23.38% |
| 3 | Communication Services | 13.54% |
| 4 | Energy | 13.02% |
| 5 | Consumer Discretionary | 7.46% |
Similar funds
Ruffer's Q4 2019 Portfolio in Review
As of Q4 2019, Ruffer held 98 positions worth $3.43B, down 2.6% from $3.52B the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Ruffer withdrew a net $572M in Q4 2019, closing 17 positions and reducing 40 holdings. Its most notable exit was Celgene Corp, an estimated $318M position sold in full.
By sector, the portfolio is most concentrated in Materials at 32% of assets, up from 24% a quarter earlier, followed by Healthcare and Communication Services.
Against the trend, Ruffer opened a new position in eHealth worth $94.7M.
- Ruffer's largest Q4 2019 buy was eHealth: 985,957 shares worth $94.7M.
- Ruffer added most to Bristol-Myers Squibb in Q4 2019, an estimated $294M increase.
- Ruffer's biggest Q4 2019 reduction was Amgen, cutting an estimated $218M.
- Ruffer fully exited Celgene Corp in Q4 2019, selling an estimated $318M.
- Ruffer's ten largest holdings make up 63% of its $3.43B portfolio in Q4 2019.
- Ruffer opened 5 new positions and closed 17 in Q4 2019.
- Ruffer's portfolio value fell 2.6% quarter-over-quarter to $3.43B.
Based on Ruffer's 13F filing for Q4 2019, filed 6 Feb 2020.